Results 1 to 10 of about 5,352 (119)

Olmesartan‐Associated Enteropathy: An Uncommon Cause of Chronic Diarrhea [PDF]

Clinical Case Reports
Olmesartan‐associated sprue‐like enteropathy is an uncommon side effect and should be considered as a differential diagnosis in patients who are on Olmesartan and presenting with chronic unexplained diarrhea.
Ahmed Sayedahmed, Hisham Sherfi, Mohamed Elobaid, Mohamed Ibrahim, Essam Arabi, Suhaib Ahmed   +5 more
doaj   +2 more sources

Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia.
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park   +5 more
doaj   +1 more source

Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts [PDF]

International Journal of Ophthalmology, 2016
AIM: To evaluate the inhibitive effect of olmesartan to fibroblast proliferation and the anti-scarring effect in Tenon’s capsule, both in vitro and in vivo.
Xuan Wang, Ya-Zhi Fan, Liang Yao, Jian-Ming Wang   +3 more
doaj   +1 more source

Olmesartan restores the protective effect of remote ischemic perconditioning against myocardial ischemia/reperfusion injury in spontaneously hypertensive rats

Clinics, 2015
OBJECTIVES: Remote ischemic perconditioning is the newest technique used to lessen ischemia/reperfusion injury. However, its effect in hypertensive animals has not been investigated.
Xin Lu, Yan-Wen Bi, Ke-Biao Chen
doaj   +1 more source

Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis

Kidney & Blood Pressure Research, 2016
Background/Aims: Blockage of the renin-angiotensin II system (RAS) prevents or delays albuminuria in diabetic patients. The aim of this study was to investigate the inhibitory mechanism of the angiotensin receptor blocker olmesartan on albuminuria in a ...
Junhui Gu, Ming Yang, Na Qi, Shuqin Mei, Jiejian Chen, Shuwei Song, Ying Jing, Meihan Chen, Liangliang He, Lijun Sun, Huimin Hu, Lin Li, Rudolf P. Wüthrich, Ming Wu, Changlin Mei   +14 more
doaj   +1 more source

Green spectrofluorimetric quantification of aspirin, olmesartan, and metoprolol in spiked human plasma

Scientific Reports, 2023
Low dose aspirin is routinely taken with antihypertensive drugs such as olmesartan and metoprolol to avoid the cardiovascular and renal outcomes associated with high blood pressure. The first spectrofluorimetric method for quantifying aspirin, olmesartan,
Ali Alqahtani, Taha Alqahtani, Reem M. Gahtani, Sherif Ramzy   +3 more
doaj   +1 more source

Sprue-Like Enteropathy and Liver Injury: A Rare Emerging Association with Olmesartan

Journal of Investigative Medicine High Impact Case Reports, 2021
Olmesartan-induced enteropathy is an underreported phenomenon, first described in 2012. While olmesartan’s antihypertensive properties were confirmed early on, its association with a sprue-like enteropathy was subsequently noted.
Mihir Odak MD, Ndausung Udongwo MD, Nasam Alfraji MD, Min Zheng MD, PhD, Saddam Zaidi MD   +4 more
doaj   +1 more source

Synthesis and Characterization of Process-Related Impurities of Antihypertensive Drug Olmesartan Medoxomil

Journal of Chemistry, 2013
Olmesartan medoxomil (1) is the latest angiotensin receptor antagonist approved by the FDA for the treatment of hypertension. During the process development of olmesartan medoxomil, three process-related impurities were observed along with the final API.
G. Venkanna, G. Madhusudhan, K. Mukkanti, A. Sankar, Y. Sampath Kumar, G. Venakata Narayana   +5 more
doaj   +1 more source

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers

Current Therapeutic Research, 2014
Background: Olmesartan is an angiotensin II receptor antagonist and is effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricemic agent for the treatment of hyperuricemia and gout. Objective: The
Kun-Yan Li, PhD, Yu Qiu, MS, Yun Jiang, BS, Chen-Hui Luo, MS, Xiao-Ping Lin, BS, Jing Wang, BS, Nong Yang, MS   +6 more
doaj   +1 more source

Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study

Cardiovascular Diabetology, 2011
Background Angiotensin II receptor blockers (ARBs), including olmesartan and candesartan, are widely used antihypertensive agents. Many clinical studies have demonstrated that ARBs have organ-protecting effects, e.g., cardioprotection, vasculoprotection ...
Nakayama Tomohiro, Takahashi Yasuo, Nishida Yayoi, Soma Masayoshi, Asai Satoshi   +4 more
doaj   +1 more source